BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31

BIODESIX INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$23.40−0.26 (-1.10%)

Close on Oct 19, 2026

Market cap: $240.93M
P/E (TTM): –
Dividend yield: –

BIODESIX INC balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Cash & Equivalents	19	26	26	43	33	62	5.47	6.09
Cash & Short-Term Investments	19	26	26	43	33	62	5.47	6.09
Receivables	9.04	8.60	7.68	5.07	3.66	15	5.29	–
Other Current Assets	4.50	4.64	5.72	5.18	7.25	8.71	2.12	–
Total Current Assets	33	39	40	53	44	86	13	–
Property, Plant & Equipment	25	28	28	5.85	4.18	3.18	2.12	–
Gross Property, Plant & Equipment	37	37	33	13	11	9.90	8.51	–
Accumulated Depreciation	-13	-9.13	-5.61	-7.02	-6.75	-6.72	-6.39	–
Operating Lease Right-of-Use Assets	3.00	1.77	1.75	2.97	1.30	–	–	–
Goodwill	15	15	15	15	15	15	15	14
Intangible Assets	3.88	5.87	7.91	9.80	12	13	15	–
Other Long-Term Assets	8.23	7.26	6.86	5.92	1.66	3.46	0.09	–
Total Assets	87	97	99	93	76	121	45	–
Accounts Payable	3.08	2.19	2.93	1.69	1.66	8.96	1.72	–
Accrued Expenses	11	10	7.71	8.22	7.67	7.79	4.18	–
Current Portion of Leases	1.36	0.72	0.25	1.54	–	–	–	–
Deferred Revenue (Current)	0.96	0.68	0.32	0.96	1.85	3.53	1.28	–
Other Current Liabilities	0.99	0.64	0.29	0.04	–	–	–	–
Total Current Liabilities	17	14	33	23	29	32	23	–
Long-Term Debt	47	36	35	25	9.99	16	24	–
Long-Term Leases	24	25	25	5.25	–	–	–	–
Operating Lease Liabilities	25	26	25	6.80	1.30	–	–	–
Other Long-Term Liabilities	1.02	0.82	0.71	0.56	1.39	1.92	0.36	–
Total Liabilities	90	76	95	72	56	80	76	–
Total Debt	47	36	35	25	9.99	16	24	–
Common Stock	0.01	0.01	0.10	0.08	0.03	0.03	0.00	–
Additional Paid-In Capital	495	483	424	388	322	300	2.32	–
Retained Earnings	-498	-462	-420	-367	-302	-259	-227	–
Shareholders' Equity	-2.47	21	4.58	21	20	41	-225	-195
Total Equity	-2.47	21	4.58	21	20	41	-225	-195
Total Liabilities & Equity	87	97	99	93	76	121	45	–
Shares Outstanding(shares)	8.25	7.27	96	78	31	27	0.25	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -20.0%
Net margin: -27.0%
Return on equity, FY2025: -383.1%

Financial strength

Current ratio: 2.85
Debt to equity: 5.12
Debt to assets: 49.1%
Cash to current liabilities: 196.2%

Valuation

P/E ratio: –
Price to sales: 2.34
Price to book: 26.35
Dividend yield: –